Literature DB >> 28540973

Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

Beata Kos-Kudła, Violetta Rosiek1, Małgorzata Borowska, Agata Bałdys-Waligórska, Tomasz Bednarczuk, Jolanta Blicharz-Dorniak, Marek Bolanowski, Agnieszka Boratyn-Nowicka, Andrzej Cichocki, Jarosław B Ćwikła, Massimo Falconi, Wanda Foltyn, Foltyn Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Barbara Jarząb, Michał Jarząb, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kamiński, Agnieszka Kolasińska-Ćwikła, Aldona Kowalska, Robert Król, Leszek Królicki, Jolanta Kunikowska, Katarzyna Kuśnierz, Paweł Lampe, Dariusz Lange, Anna Lewczuk-Myślicka, Andrzej Lewiński, Michał Lipiński, Magdalena Londzin-Olesik, Bogdan Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Joanna Pilch-Kowalczyk, Marek Ruchała, Lucyna Siemińska, Anna Sowa-Staszczak, Teresa Starzyńska, Katarzyna Steinhof-Radwańska, Janusz Strzelczyk, Krzysztof Sworczak, Anhelli Syrenicz, Andrzej Szawłowski, Marek Szczepkowski, Ewa Wachuła, Wojciech Zajęcki, Anna Zemczak, Wojciech Zgliczyński.   

Abstract

This article presents updated diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine tumours (PNEN), proposed by the Polish Network of Neuroendocrine Tumours. The guidelines contain new data received in the years 2013-2016, which confirm previous recommendations, and have led to modification of previous guidelines or have resulted in the formulation of new guidelines. Biochemical and imaging (anatomical and functional) tests are of great importance in diagnostics, as well as histopathological diagnosis to determine the management of PNEN patients, but they must be confirmed by an immunohistochemical examination. PNEN therapy requires collaboration among the members a multidisciplinary team of specialists experienced in the management of these neoplasms. Surgery is the basic form of treatment in many cases. Further therapy requires a multidirectional procedure; therefore, the rules of biotherapy, peptide receptor radionuclide therapy, molecular targeted therapy, and chemotherapy are discussed.

Entities:  

Keywords:  diagnostics; functional; guidelines; non-functional; pancreatic neuroendocrine neoplasms; therapy

Mesh:

Year:  2017        PMID: 28540973     DOI: 10.5603/EP.2017.2016

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  7 in total

1.  Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Authors:  Stephan Petersenn; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

2.  Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.

Authors:  Teresa Starzyńska; Jakub Karczmarski; Agnieszka Paziewska; Maria Kulecka; Katarzyna Kuśnierz; Natalia Żeber-Lubecka; Filip Ambrożkiewicz; Michał Mikula; Beata Kos-Kudła; Jerzy Ostrowski
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

3.  NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.

Authors:  Anna Malczewska; Magdalena Witkowska; Karolina Makulik; Agnes Bocian; Agata Walter; Joanna Pilch-Kowalczyk; Wojciech Zajęcki; Lisa Bodei; Kjell E Oberg; Beata Kos-Kudła
Journal:  Endocr Connect       Date:  2019-03-01       Impact factor: 3.335

Review 4.  Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a focus on ultrasound.

Authors:  Joanna Walczyk; Anna Sowa-Staszczak
Journal:  J Ultrason       Date:  2019-09-30

5.  Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study.

Authors:  Barbara Bober; Marek Saracyn; Kornelia Zaręba; Arkadiusz Lubas; Paweł Mazurkiewicz; Ewelina Wilińska; Grzegorz Kamiński
Journal:  J Clin Med       Date:  2022-02-10       Impact factor: 4.241

6.  Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors.

Authors:  Bartosz Molasy; Patryk Zemła; Sławomir Mrowiec; Ewa Grudzińska; Katarzyna Kuśnierz
Journal:  Ther Clin Risk Manag       Date:  2022-07-29       Impact factor: 2.755

7.  A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.

Authors:  Przemysław Soczomski; Beata Jurecka-Lubieniecka; Aleksandra Krzywon; Alexander Jorge Cortez; Stanisław Zgliczynski; Natalia Rogozik; Małgorzata Oczko-Wojciechowska; Agnieszka Pawlaczek; Tomasz Bednarczuk; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.